Patent intelligence · US
US 8895722
Splice-region antisense composition and method
Splice-region antisense composition and method
Patent details — US 8895722
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 25, 2014
- Expiration
- Nov 20, 2034
- Applicant
- Sarepta Therapeutics, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P13/08
Quick answer
US 8895722 (Splice-region antisense composition and method) is held by Sarepta Therapeutics, Inc.. Status: granted. Granted Nov 25, 2014. Expires Nov 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sarepta Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61P, A61P13/08, A61P17/00, A61P29/00
More from Sarepta Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377150
Exon skipping oligomer conjugates for muscular dystrophy
granted -
US 12370261
Chimeric peptides for antisense delivery
granted -
US 12286630
Treatment methods for muscular dystrophy
granted -
US 12239715
Peptide oligonucleotide conjugates
granted -
US 12168059
Trimeric peptides for antisense delivery
granted -
US 12138312
Cell-penetrating peptides for antisense delivery
granted -
US 12139709
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
granted -
US 12121532
Modified antisense oligomers for exon inclusion in spinal muscular atrophy
granted
Frequently asked questions
What is US patent 8895722?
US 8895722 (Splice-region antisense composition and method) is held by Sarepta Therapeutics, Inc.. Status: granted. Granted Nov 25, 2014. Expires Nov 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8895722?
Sarepta Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 102 pharmaceutical patents for this assignee.
When does US 8895722 expire?
Our index shows an expiration date of Nov 20, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.